Global Galactosemia Treatment Market – Industry Trends and Forecast to 2030

Galactosemia Treatment Market Analysis and Size

Classic galactosemia is being diagnosed in several new-born screening programs globally in the range of 1/16,000 to 1/48,000 new-borns, based on the program's diagnostic criteria. All the ethnic groups have been severely affected by the disease. Individuals of Irish heritage have a higher occurrence of galactosemia. Approximately 100% of infants can be diagnosed in screening programs using a blood sample from the heel stick.

Data Bridge Market Research analyses a growth rate in the galactosemia treatment market in the forecast period 2023-2030. The expected CAGR of galactosemia treatment market is tend to be around 6.7% in the mentioned forecast period. The market value is 469.48 million in 2022, and it would grow up to USD 788.74 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Galactosemia Treatment Market Scope and Segmentation

Market Definition

Galactosemia is a type of autosomal recessive galactose metabolism condition that is caused by mutations in any of the enzymes in the galactose metabolism pathway. Lactose-restricted diets for infants and children suffering from galactosemia should include lactose-free milk replacements and other foods such soybean products. Speech therapy may greatly benefit children with apraxia of speech or dysarthria. Infection can be controlled in the new-born period with many suitable treatment.  

Galactosemia Treatment Market Dynamics

Drivers

• Rising Cases of Galactosemia

The growing prevalences of galactosemia is a main factor boosting the market's growth rate during the forecast period. Galactosemia is diagnosed in the range of 1/16,000 to 1/48,000 births through global newborn screening programs. A high frequency of galactosemia occurs in individuals with Irish ancestry. Around 1 in 4 offspring has a 25% chance of developing galactosemia if both the parents have a nonworking copy of the gene which causes the disease. Therefore, this increasing incidence demands increased medication rates, thus boosting market growth.

• Increased Healthcare Expenditure

A major factor prompting the growth rate of galactosemia treatment market is the increasing healthcare expenditure that helps in improving its improved infrastructure. Moreover, numerous government organizations aim to improve the healthcare infrastructure by growing funding, which will influence the market dynamics. Thus, it boost the market growth.

Opportunities

• Increasing Treatment Methods

Treatment methods such as speech therapy may be essential for children having childhood apraxia of speech or dysarthria. Individual education plans or professional help with learning skills may be required for school age children, depending on psychological developmental assessments. Furthermore, hormone replacement therapies may also be used in delayed puberty and later in adolescence with premature ovarian insufficiency (POI). Suitable treatment as in with proper antibiotic drugs may be used widely to control infection in the new born period. Genetic counseling is advised for families with children who suffers from galactosemia. Therefore, all these treatment methods are boosting the growth of the market.

Restraints/Challenges

• Complications Associated with Treatment Methods

There are many complications that are found to be associated with the disease that can have possible complications such as mental disability, cirrhosis, cataracts, delayed speech development and others will restrain and further hinder the market's growth rate during the forecast period. Thus, all these restrain the market growth.

• High Cost of Treatment

The high cost that is required for the different treatment methods impedes market growth. Many market players make some huge investments in manufacturing advanced treatment procedures to increase the recovery process, and in return, the cost is increased.

This galactosemia treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the galactosemia treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In 2022, Applied Therapeutics, Inc. announced a regulatory update on the AT-007 Galactosemia program. The trial named ACTION-Galactosemia Kids Phase 3 trial compares the effects of AT-007 treatment and placebo for different parameters such as speech, behavior, cognition, and motor skills over time. A closed group assesses clinical outcomes with a gap of six months. The initial evaluation has been conducted in the first quarter of 2022.

Global Galactosemia Treatment Market Scope

The galactosemia treatment market is segmented on the basis of type, diagnosis, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Classic Galactosemia
• Clinical Variant Galactosemia
• Biochemical Variant Galactosemia

Route of Administration

• Oral
• Parenteral
• Others

Diagnosis

• Genetic Testing
• Blood tests
• Urine tests
• Others

Treatment

• Hormone replacement therapy
• Speech therapy
• Medication
• Antibiotics
• Others
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Galactosemia Treatment Regional Analysis/Insights

The galactosemia treatment market is analyzed and market size insights and trends are provided by type, diagnosis, treatment, route of administration, end-users and distribution channel as referenced above.

The major countries covered in the galactosemia treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market in the forecast period due to the increasing occurrence of galactosemia and increasing healthcare expenditure,which will further boost the market’s growth rate in this region. Moreover, rising presence of major market players will further boost the market’s growth rate in this region.

Asia-Pacific is considered to grow over the coming years because of the development of healthcare infrastructure in this region. Furthermore, increasing government initiatives will further boost this region's market’s growth rate.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. 

Competitive Landscape and Global Galactosemia Treatment Share Analysis

The galactosemia treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to galactosemia treatment market

Key players operating in the galactosemia treatment market include:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• Merck & Co., Inc. (U.S.)
• Abbvie, Inc (U.S.)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Hikma Pharmaceuticals PLC (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• Bayer AG (Germany)
• Boehringer Ingelheim International GmbH. (Germany)
• Dr. Reddy’s Laboratories Ltd. (India)
• Gilead Sciences, Inc. (U.S.)
• Amgen Inc. (U.S.)
• Lilly (U.S.)
• Lupin (India)

SKU-68638